Loading company…
Shanghai ophthalmology drug developer with a pipeline of eye disease treatments, largely licensed from overseas partners.
OcuMension was established in 2018 in Shanghai, China, and develops ophthalmic drugs covering both the anterior and posterior segments of the eye. Over 60% of its drugs are licensed from international pharmaceutical companies, including EyePoint, NicOx SA, Huonland, Senju and SanBio. The company has completed two financing rounds raising about USD 200 million, and its business centers on licensing and commercializing overseas drugs in China.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in